Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 0.5 | 0.5 |
Schistosoma mansoni | DNA polymerase eta | 0.0023 | 0.5 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.5 | 0.5 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Echinococcus multilocularis | dna polymerase eta | 0.0023 | 0.5 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.5 | 0.5 |
Echinococcus multilocularis | dna polymerase kappa | 0.0023 | 0.5 | 0.5 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.5 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Echinococcus granulosus | dna polymerase kappa | 0.0023 | 0.5 | 0.5 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.5 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0928 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 0.7943 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 26.6795 uM | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.